New drugs and combinations for malignant glioma

FORUM - Trends in Experimental and Clinical Medicine

Volumn 13, Issue 1, 2003, Pages 61-75

  Stupp, Roger ^a,b   Rüegg, Curzio ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Frontiers in Genetics National Center for Competence in Research   (Switzerland)

Author keywords

Glioma; Oligoastrocytoma

Indexed keywords

6 O BENZYLGUANINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; GEMCITABINE; IRINOTECAN; LOBRADIMIL; LOMUSTINE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; NEW DRUG; NITROSOUREA DERIVATIVE; PACLITAXEL; PRINOMASTAT; PROCARBAZINE; RETINOIC ACID; TAXANE DERIVATIVE; TEMOZOLOMIDE; THALIDOMIDE; TIRAPAZAMINE; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG POTENTIATION; EVIDENCE BASED MEDICINE; GLIOBLASTOMA; HUMAN; LETHARGY; META ANALYSIS; METHODOLOGY; OUTCOMES RESEARCH; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 4544285241     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Walker MD et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 1980; 303: 1323-1329.
2. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J. Clin. Oncol. 2001; 19: 509-518.
3. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018.
4. Cairncross JG et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 1998; 90: 1473-1479.
5. Vos MJ et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 2003; 60: 826-830.
6. Macdonald DR et al. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 1990; 8: 1277-1280.
7. Wong ET et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J. Clin. Oncol. 1999; 17: 2572.
8. Lang FF et al. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro-oncol. 2002; 4: 268-277.
9. Brem H et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995; 345: 1008-1012.
10. Westphal M et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol. 2003; 5: 79-88.
11. Olivi A et at. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J. Clin. Oncol. 2003; 21: 1845-1849.
12. Stupp R et al. Current and future developments in the use of temozolomide in the treatment of brain tumors. Lancet Oncol. 2001; 2: 552-560.
13. Brada M et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 2001; 12: 259-266.
14. Yung WK et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 2000; 83: 588-593.
15. Yung WK et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 1999; 17: 2762-2771.
16. Lashford LS et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncotogy Intergroup Study. J. Clin. Oncol. 2002; 20: 4684-4691.
17. Gilbert MR et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol 2002; 4: 261-267.
18. Brock CS et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998; 58: 4363-4367.
19. Denis L et al. Protracted daily administration of temozolomide is feasible: a phase I and pharmacokinetic-pharmacodynamic study. Proc. Am. Soc. Clin. Oncol. 2000; 19: 202a (abs. 786).
20. Figueroa J et al. Protracted cyclic administration of temozolomide is feasible; a phase I, pharmacokinetic and pharmacodynamic study. Proc. Am. Soc. Clin. Oncol. 2000; 19: 222a (Abstr. 868).
21. Tolcher AW et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer 2003; 88: 1004-1011.
22. Quinn J et al. Phase 1 trial of Temodar plus O6-benzylguanine in the treatment of patients with recurrent or progressive cerebral anaplastic gliomas. Proc. Am. Soc. Clin. Oncol. 2003; 22: 103 (Abstr 411).
23. Khan RB et al. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol. 2002; 4: 39-43.
24. Hughes MA et al. Low CD4 counts and PCP prophylaxis in patients with primary brain tumors treated with steroids and radiation. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57: S369-370.
25. Mahindra AK and Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J. Neurooncol. 2003; 63: 263-270.
26. Blaney SM et al. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother. Pharmacol. 1998; 41: 464-468.
27. Friedman HS et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 1999; 17: 1516-1525.
28. Buckner JC et al. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer 2003; 97: 2352-2358.
29. Raymond E et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann. Oncol. 2003; 14: 603-614.
30. Rajkumar SV. Current status of thalidomide in the treatment of cancer. Oncology (Huntingt) 2001; 15: 867-874; discussion 877-869.
31. Fanelli M et al. Thalidomide: a new anti-cancer drug? Expert. Opin. Investig. Drugs 2003; 12: 1211-1225.
32. Fine HA et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. 2000; 18: 708-715.
33. Rajkumar SV et al. A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma. J. Neurooncol. 2000; 49: 255-261.
34. Fellner S et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest. 2002; 110: 1309-1318.
35. Chamberlain MC and Kormanik P. Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. J. Neurooncol. 1999; 43: 71-78.
36. Sanson M et al. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J. Neurooncol. 2000; 50: 245-249.
37. Fetell MR et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J. Clin. Oncol. 1997; 15: 3121-3128.
38. Langer CJ et al. Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 2001; 51: 113-119.
39. Fisher BJ et al. Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507. J. Clin. Oncol. 2001; 19: 1111-1117.
40. Gertler SZ et al. NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Ann. Oncol. 2000; 11: 315-318.
41. Weller M et al. Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study. Cancer 2001; 91: 423-427.
42. Del Rowe J et al. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J. Clin. Oncol. 2000; 18: 1254-1259.
43. Prados MD et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-oncol. 2003; 5: 96-103.
44. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 19: 6642-6650.
45. Groves MD et at. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 2002; 20: 1383-1388.
46. Levin V et al. Randomized phase II study of temozolomide (TMZ) with and without the matrix metalloprotease, (MMP) inhibitor prinomastat in patients (pts) with glioblastoma multiforme (GBM) following best surgery and radiation therapy. Proc. Am. Soc. Clin. Oncol. 2002; 21: 26a (abs. 100).
47. Newlands ES, Foster T, Zaknoen S. Phase 1 study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br. J. Cancer 2003; 89: 248-251.
48. Yung WK et al. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin. Cancer Res. 1996; 2: 1931-1935.
49. Stupp R et al. Temozolomide and irinotecan (CPT-11) for for primary brain tumors. A dose escalation study. Proc. Am. Soc. Clin. Oncol. 2003; 22: 22 (Abstr 415).
50. Fulton D, Urtasun R, Forsyth P Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J. Neurooncol. 1996; 27: 149-155.
51. Korones DN et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 2003; 97: 1963-1968.
52. Levin VA et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylomithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin. Cancer Res. 2000; 6: 3878-3884.
53. Levin VA et al. Phase III Randomized Study of Postradiotherapy Chemotherapy with Combination alpha-Difluoromethylor-nithine-PCV versus PCV for Anaplastic Gliomas. Clin. Cancer Res. 2003; 9: 981-990.
54. Quinn JA et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol. 2002; 20: 2277-2283.
55. Boiardi A et al. Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte O6-alkylguanine-DNA alkyltransferase activity. J. Neurooncol. 2001; 52: 149-156.
56. van Rijn J et al. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47: 779-784.
57. Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozotomide-treated human glioblastoma cells. Cancer Res. 2001; 61: 1957-1963.
58. Wick W et al. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res. 2002; 62: 1915-1919.
59. Stupp R et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 2002; 20: 1375-1382.
60. Stupp R, Hegi M. Recent developments in the management of malignant glioma. In Perry M, ed; ASCO 2003 Educational Book. Alexandria, VA: Am. Soc. of Clin. Onc. 2003; 779-788.
61. Weller M et al. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J. Clin. Oncol. 2003; 21: 3276-3284.
62. Tremont-Lukats IW, Gilbert MR. Advances in molecular therapies in patients with brain tumors. Cancer Control 2003; 10: 125-137.
63. Puduvalli VK, Sawaya R. Antiangiogenesis - therapeutic strategies and clinical implications for brain tumors. J. Neurooncol. 2000; 50: 189-200.
64. Kirsch M, Schackert G, Black PM. Antiangiogenic treatment strategies for malignant brain tumors. J. Neurooncol. 2000; 50: 149-163.
65. Rüegg C and Mariotti A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell. Mol. Life Sci. 2003; 60: 1135-1157.
66. Davis DW et al. Surrogate markers in antiangiogenesis clinical trials. Br. J. Cancer 2003; 89: 8-14.
67. Grossman SA et al. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. J. Clin. Oncol. 2001; 19: 3260-3266.
68. Prados M et al. Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc. Am. Soc. Clin. Oncol. 2003; 22: 99 (Abstr 394).
69. Mauro MJ et al. ST157 1: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol. 2002; 20: 325-334.
70. George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin. Oncol. 2001; 28: 27-33.
71. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (ST1571). Eur. J. Cancer 2002; 38 Suppl 5: S28-36.
72. Nomura M et al. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation. Mol. Carcinog. 2003; 38: 25-32.
73. Mita MM, Mita A, Rowinsky EK. The Molecular Target of Rapamycin (mTOR) as a Therapeutic Target Against Cancer. Cancer Biol. Ther. 2003; 2: S169-177.
74. Konopka G and Bonni A. Signaling pathways regulating gliomagenesis. Curr. Mol. Med. 2003; 3: 73-84.
75. Sulis ML and Parsons R. PTEN: from pathology to biology. Trends. Cell. Biol. 2003; 13: 478-483.
76. Huang S and Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 2003; 3: 371-377.
77. Buckner J, et al. A phase I study of the safety, tolerability and pharmacokinetics of intravenous CCI-779 given once daily for 5 days every 2 weeks to patients with CNS tumors. Proc. Soc. Neuro-oncol. 4. 365 (abs. 208), 2002.
78. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
79. Eliceiri BP and Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J. 2000; 6 Suppl 3: S245-249.
80. Smith JW Cilengitide Merck. Curr. Opin. Investig. Drugs 2003; 4: 741-745.
81. Nabors LB, et al., for the New Approaches to Brain Tumor Therapy (NABTT) CNS consortium. A phase I trial of EMD, 121974 for treatment of patients with recurrent malignant gliomas. Proc. Soc. Neuro-oncol. 4: 373 (Abstr. 236), 2002.
82. Varner JA and Cheresh DA. Integrins and cancer. Curr. Opin. Cell. Biol. 1996; 8: 724-730.
83. Vane JR and Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann. Rev. Pharmacol. Toxicol 1998; 38: 97-120.
84. Dormond O and Rüegg C. Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives. Drug Res. Updates 2001; 4: 314-321.
85. Ruegg C, Zaric J, Stupp R. Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality. Ann. Med. Rev. 2003; in press.
86. Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-Cancer Drugs 2002; 13: 127-137.
87. Joki T et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 2000; 60: 4926-4931.
88. Prayson RA et al, Cyclooxygenase-2 (COX- 2) expression by immunohistochemistry in glioblastoma multiforme. Ann. Diagn. Pathol. 2002; 6: 148-153.
89. Shono T et al. Cyclooxygenase, 2 expression in human gliomas, prognostic significance and molecular correlations. Cancer Res. 2001; 61: 4375-4381.
90. Steinauer KK et al. Radiation induces upregulation of cyclooxygenase,2 (COX-2) protein in PC-3 cells. Int. J. Radiat. Oncol. 2000; 48: 325-328.
91. Hanson WR and Thomas C. 16, 16-dimethyl prostaglandin E2 increases survival of murine intestinal stem cells when given before photon radiation. Radiat. Res. 1983; 96: 393-398.
92. Furuta Y et al. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res. 1988; 48: 3008-3013.
93. Kishi K et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 2000; 60: 1326-1331.
94. Milas L et al. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. 1999; 91: 1501-1504.
95. Huh YH et al, Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E2 production by epidermal growth factor via mitogen-activated protein kinase in articular chondrocytes. J. Biol. Chem. 2003; 278: 9691-9697.
96. Pai R et al, Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Med. 2002; 8: 289-293.